Inspire Investing LLC Buys 22,436 Shares of Royalty Pharma PLC $RPRX

Inspire Investing LLC grew its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 226.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,357 shares of the biopharmaceutical company’s stock after acquiring an additional 22,436 shares during the period. Inspire Investing LLC’s holdings in Royalty Pharma were worth $1,166,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Victory Capital Management Inc. raised its stake in shares of Royalty Pharma by 270.4% in the first quarter. Victory Capital Management Inc. now owns 3,623,134 shares of the biopharmaceutical company’s stock worth $112,788,000 after acquiring an additional 2,644,923 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Royalty Pharma by 8.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,847,934 shares of the biopharmaceutical company’s stock worth $88,656,000 after acquiring an additional 226,048 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Royalty Pharma by 37.0% in the first quarter. AQR Capital Management LLC now owns 2,608,090 shares of the biopharmaceutical company’s stock worth $80,381,000 after acquiring an additional 704,414 shares during the last quarter. Invesco Ltd. raised its stake in shares of Royalty Pharma by 34.1% in the first quarter. Invesco Ltd. now owns 1,284,418 shares of the biopharmaceutical company’s stock worth $39,984,000 after acquiring an additional 326,525 shares during the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of Royalty Pharma by 7.5% in the first quarter. Alliancebernstein L.P. now owns 1,241,051 shares of the biopharmaceutical company’s stock worth $38,634,000 after acquiring an additional 86,873 shares during the last quarter. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Stock Down 0.4%

Shares of NASDAQ:RPRX opened at $36.01 on Friday. Royalty Pharma PLC has a 52 week low of $24.05 and a 52 week high of $38.00. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.26 and a current ratio of 1.26. The company has a market capitalization of $21.00 billion, a PE ratio of 20.82, a PEG ratio of 2.27 and a beta of 0.60. The company has a 50 day moving average price of $36.18 and a two-hundred day moving average price of $34.65.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.10 by $0.04. Royalty Pharma had a net margin of 44.23% and a return on equity of 25.54%. The firm had revenue of $578.67 million during the quarter, compared to the consensus estimate of $750.06 million. Analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were paid a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend was Friday, August 15th. Royalty Pharma’s dividend payout ratio is presently 50.87%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Wall Street Zen downgraded shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Saturday, September 13th. The Goldman Sachs Group initiated coverage on shares of Royalty Pharma in a research note on Tuesday, September 30th. They set a “buy” rating and a $42.00 price target for the company. Morgan Stanley dropped their price target on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a research note on Friday. Citigroup boosted their price target on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, July 22nd. Finally, Weiss Ratings raised shares of Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $46.00.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.